[go: up one dir, main page]

JPH05502434A - 医薬組成物およびその用途 - Google Patents

医薬組成物およびその用途

Info

Publication number
JPH05502434A
JPH05502434A JP1511635A JP51163589A JPH05502434A JP H05502434 A JPH05502434 A JP H05502434A JP 1511635 A JP1511635 A JP 1511635A JP 51163589 A JP51163589 A JP 51163589A JP H05502434 A JPH05502434 A JP H05502434A
Authority
JP
Japan
Prior art keywords
treatment
compositions
acid
fusidic acid
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP1511635A
Other languages
English (en)
Japanese (ja)
Inventor
ベンツェン、クラウス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JPH05502434A publication Critical patent/JPH05502434A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/003—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring the S atom directly linked to a ring carbon atom of the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C07J41/0027—Azides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
JP1511635A 1988-10-28 1989-10-30 医薬組成物およびその用途 Pending JPH05502434A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK6039/88 1988-10-28
DK603988A DK603988D0 (da) 1988-10-28 1988-10-28 Farmaceutisk praeparat

Publications (1)

Publication Number Publication Date
JPH05502434A true JPH05502434A (ja) 1993-04-28

Family

ID=8146989

Family Applications (1)

Application Number Title Priority Date Filing Date
JP1511635A Pending JPH05502434A (ja) 1988-10-28 1989-10-30 医薬組成物およびその用途

Country Status (5)

Country Link
EP (1) EP0561772A1 (fr)
JP (1) JPH05502434A (fr)
CA (1) CA2001790A1 (fr)
DK (1) DK603988D0 (fr)
WO (1) WO1990004398A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643901A (en) * 1990-06-11 1997-07-01 Fujisawa Pharmaceutical Co., Ltd. Medicament for treating idiopathic thrombocytopenic purpura
WO1991019495A1 (fr) * 1990-06-11 1991-12-26 Fujisawa Pharmaceutical Co., Ltd. Utilisation d'un compose de macrolide tel que le fk 506 pour fabriquer un medicament destine a traiter la purpura thrombocytopenique idiopathique et la maladie de basedow
GB2252041A (en) * 1991-01-23 1992-07-29 Fujisawa Pharmaceutical Co Use of macrolide compounds in treatment of autoimmune myocarditis
EP1304333A3 (fr) * 1996-07-11 2005-03-09 Inflazyme Pharmaceuticals, Ltd. Stéroides oxygénés en position 6,7 et leurs utilisations
US6046185A (en) 1996-07-11 2000-04-04 Inflazyme Pharmaceuticals Ltd. 6,7-oxygenated steroids and uses related thereto
WO1998042377A1 (fr) 1997-03-21 1998-10-01 Chugai Seiyaku Kabushiki Kaisha Substances servant a la prevention ou au traitement de maladies liees a la cellule-t sensibilisee contenant comme principe actif des antagonistes de l'il-6
US7544465B2 (en) * 2001-09-27 2009-06-09 The Wistar Institute Methods and compositions for monitoring cell migration and identifying clinically relevant cytotoxic T lymphocyte activity
US9233107B2 (en) * 2007-09-14 2016-01-12 Biogen Ma Inc. Compositions and methods for the treatment of progressive multifocal leukoencephalopathy (PML)
RU2536252C2 (ru) * 2008-12-19 2014-12-20 Сулур Субраманиам ВАНАНГАМУДИ Новый дерматологический крем, изготовленный с использованием фусидата натрия
JP2012517995A (ja) * 2009-02-18 2012-08-09 スラー サブラマニアン ヴァナンガムディ フシジン酸ナトリウムを用いて作製した皮膚用医薬品ゲルおよびその作製方法
US8895542B2 (en) * 2009-04-13 2014-11-25 Vanangamudi Subramaniam Sulur Medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer and a process to make it
CN106749475B (zh) * 2017-01-13 2018-11-23 广东工业大学 一种夫西地酸化学修饰物的制备及用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7411402A (nl) * 1973-09-13 1975-03-17 Leo Pharm Prod Ltd Werkwijze voor het bereiden van een middel tegen arthritis.
GB1490852A (en) * 1974-09-12 1977-11-02 Leo Pharm Prod Ltd Fusidic acid derivatives
GB8706313D0 (en) * 1987-03-17 1987-04-23 Health Lab Service Board Treatment & prevention of viral infections

Also Published As

Publication number Publication date
EP0561772A1 (fr) 1993-09-29
CA2001790A1 (fr) 1990-04-28
WO1990004398A1 (fr) 1990-05-03
DK603988D0 (da) 1988-10-28

Similar Documents

Publication Publication Date Title
Flowers et al. Pathophysiology and treatment of graft-versus-host disease
Cooper et al. Acceleration of onset of collagen‐induced arthritis by intra‐articular injection of tumour necrosis factor or transforming growth factor‐beta
JP6472142B2 (ja) Ｈｃ−ｈａ／ｐｔｘ３複合体を含む組成物およびその使用方法
KR102033276B1 (ko) T 조절 세포의 생체 내 확장 방법
KR101833204B1 (ko) 림프양 조직에 줄기 세포와 조상 세포 결합을 저해하고, 그리고 림프 조직에서 배 중심을 재생하기 위한 조성물과 방법
TW201927782A (zh) 作為C5aR抑制劑之經二芳基取代之6,5-稠合環化合物
EP0583360A1 (fr) Compositions pour la prevention et/ou le traitement de processus pathologiques
CA2815542C (fr) Utilisation d'une composition constituee de spironolactone, qui presente une action inhibitrice de l'activation de lymphocytes t utiles dans la prevention et/ou le traitement de la sclerose en plaques
JP7262100B2 (ja) 長期寛容を誘導するためのおよびアテローム性動脈硬化症におけるマクロファージ蓄積を解決するための自然免疫システムの標的化
AU2014244744A1 (en) Pharmaceutical composition for inhibiting immune response through inducing differentiation into regulator T cells and promoting proliferation of regulator T cells
JP2021512874A (ja) 単離ミトコンドリアを含む関節リウマチの予防または治療のための医薬組成物
JP5541915B2 (ja) 自己免疫疾患を治療する方法
JPH05502434A (ja) 医薬組成物およびその用途
Waegell et al. A420983, a novel, small molecule inhibitor of LCK prevents allograft rejection
Wang et al. Effect of rapamycin and interleukin-2 on regulatory CD4+ CD25+ Foxp3+ T cells in mice after allogenic corneal transplantation
US11759423B2 (en) Exosome preparation for treating disease and application thereof
Buchele et al. Th17 cell-mediated colitis is positively regulated by interferon regulatory factor 4 in a T cell-extrinsic manner
Heine et al. Induction of the immunological bystander reaction by plant extracts
US20140011755A1 (en) Cardiac Glycosides for Treating Autoimmune Disease
Dalakas Inflammatory myopathies
JPH07506372A (ja) インビボでのｉｌ−６産生を調節する組成物および方法
AU757489B2 (en) Method for inhibiting cytokine production by cells
CN112656801A (zh) 孕激素在治疗细胞因子释放综合征中的应用
ES2257666T3 (es) Uso de (3-(2-etilfenil)-5-metoxifenil)-1h-(1,2,4)-triazol para el tratamiento de enfermedades autoinmunes.
Chae et al. T Cell-specific immunosuppression using tautomycetin or PTD-conjugated protein drugs